Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F A Greco

Showing results (91-100 of 313) with videos related to

Pageof 32
Sort By:
Cancer Treatment Reviews|September 1, 1980
Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusionK Hande, J Gay, J Gober, et al.
Journal of the Tennessee Medical Association|February 1, 1981
Multiple myeloma with extra-osseous metastasesP M Bihl, D A Clark, F A Greco
Journal of the Tennessee Medical Association|November 1, 1980
Oncology Grand Rounds: recent trends in the treatment of acute leukemia in adultsC E McKay, S N Wolff, F A Greco
Seminars in Oncology|August 7, 1999
Weekly administration of docetaxel (Taxotere): summary of clinical dataJ D Hainsworth, H A Burris, F A Greco
American Journal of Clinical Oncology|April 1, 1988
Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary siteJ D Hainsworth, T W Dial, F A Greco
Cancer Treatment Reports|November 1, 1979
Phase I evaluation of a weekly schedule of anguidine. Southeastern Cancer Study Group Committee on Gastrointestinal MalignanciesP A DeSimone, F A Greco, H F Lessner
Annals of Internal Medicine|September 1, 1988
Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entityJ D Hainsworth, D H Johnson, F A Greco
Annals of Internal Medicine|April 1, 1986
Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndromeF A Greco, W K Vaughn, J D Hainsworth
Journal of the Tennessee Medical Association|May 1, 1979
Bone marrow transplantation-1979P G Beatty, R K Oldham, F A Greco
Cancer Treatment Reviews|March 1, 1991
A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancerF A Greco, D H Johnson, J D Hainsworth
Pageof 32

Showing results (91-100 of 313) with videos related to

Sort By:
Pageof 32
Cancer Treatment Reviews|September 1, 1980
Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusionK Hande, J Gay, J Gober, et al.
Journal of the Tennessee Medical Association|February 1, 1981
Multiple myeloma with extra-osseous metastasesP M Bihl, D A Clark, F A Greco
Journal of the Tennessee Medical Association|November 1, 1980
Oncology Grand Rounds: recent trends in the treatment of acute leukemia in adultsC E McKay, S N Wolff, F A Greco
Seminars in Oncology|August 7, 1999
Weekly administration of docetaxel (Taxotere): summary of clinical dataJ D Hainsworth, H A Burris, F A Greco
American Journal of Clinical Oncology|April 1, 1988
Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary siteJ D Hainsworth, T W Dial, F A Greco
Cancer Treatment Reports|November 1, 1979
Phase I evaluation of a weekly schedule of anguidine. Southeastern Cancer Study Group Committee on Gastrointestinal MalignanciesP A DeSimone, F A Greco, H F Lessner
Annals of Internal Medicine|September 1, 1988
Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entityJ D Hainsworth, D H Johnson, F A Greco
Annals of Internal Medicine|April 1, 1986
Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndromeF A Greco, W K Vaughn, J D Hainsworth
Journal of the Tennessee Medical Association|May 1, 1979
Bone marrow transplantation-1979P G Beatty, R K Oldham, F A Greco
Cancer Treatment Reviews|March 1, 1991
A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancerF A Greco, D H Johnson, J D Hainsworth
Pageof 32